Progesterone receptor membrane component 1 increases hormone induced proliferation of breast cancer cells——E2 vs sequential combination vs continuous combination

doi:10.3969/j.issn.1006-7795.2019.02.016

Abstract

Abstract: Objective To investigate the effect of progesterone receptor membrane component 1 (PGRMC1) on the risk of hormone induced breast cancer, and compare the effects of different treatment regimens:estradiol (E2)/sequential combination/continuous combination(E2/DRSP、E2/NET) on breast cancer proliferation. Methods After stabilized transfection by lipofection, T47D cells transfected with vector(T47D-HA-vector) or PGRMC1(T47D-HA-PGRMC1) were stimulated with E2 alone (0.1, 0.01, 0.001 nmol/L), or sequential/continuous combination. CCK-2 method was performed to measure cell proliferation. Results When treated with E2 (0.001, 0.01, 0.1 nmol/L) alone, T47D-HA-vector cells did not show significant proliferation (P>0.05). At concentration of 0.1 nmol/L, T47D-HA-PGRMC1 cell reached a significant increase in cell proliferation compared with the control group (56%, P<0.05) and compared with T47D-HA-vector group (36%, P<0.05); when treated with sequential combination, T47D-HA-PGRMC1 cell under E2/NET treatment (E2=0.001 nmol/L) showed a significant increase in cell proliferation compared with the control group (82%, P<0.05) and T47D-HA-vector group (63%, P<0.05). Under the same stimulation, when the concentration of E2 reached 0.1 nmol/L, T47D-HA-vector showed a significant increase compared with the control group (37%, P<0.05), and for the T47D-HA-PGRMC1 cell line, when under E2/drospirenone (DRSP) or E2/norethisterone (NET) stimulation (E2=0.1 nmol/L), a significant increase compared with the control group (105%, 170%, P<0.05) and T47D-HA-vector group (84%, 133%, P<0.05) was observed; when treated with the continuous combination, the T47D-HA-PGRMC1 cell line showed a significant increase in cell proliferation under E2/DRSP or E2/NET stimulation (E2=0.001 nmol/L) compared with the control group (77%, 158%, P<0.05) and T47D-HA-vector group(60%, 136%, P<0.05). The T47D-HA-vector cell line showed a significant increase under E2/NET stimulation (E2=0.1 nmol/L) compared with the control group (44%, P<0.05), and the T47D-HA-PGRMC1 cell line under E2/DRSP or E2/NET stimulation (E2=0.1 nmol/L) showed a significant increase in cell proliferation compared with the control group (129%, 174%, P<0.05) and T47D-HA-vector group (97%, 131%, P<0.05). Conclusion PGRMC1 can significantly promote the proliferation of breast cancer cells induced by sequential/continuous combination. Compared with the sequential combination, the continuous combination promoted a higher proliferation of T47D.

Key words: progesterone receptor membrane component 1, sequential combination, continuous combination, breast cancer, cell proliferation

CLC Number:

R711

Li Xue, Ruan Xiangyan, Gu Muqing, Cai Guiju, Zhao Yue, Alfred O. Meuck. Progesterone receptor membrane component 1 increases hormone induced proliferation of breast cancer cells——E2 vs sequential combination vs continuous combination[J]. Journal of Capital Medical University, 2019, 40(2): 237-243.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2019.02.016

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2019/V40/I2/237

References

[1] Zhou M G, Li Y C, Wang H D, et al.Analysis on life expectancy and healthy life expectancy in China,1990-2015[J].Zhonghua Liu Xing Bing Xue Za Zhi, 2016, 37(11):1439-1443.
[2] 聂广宁, 王小云, 杨洪艳,等.中国城市女性绝经年龄影响因素调查[J].中国妇幼保健, 2011, 26(8):1191-1193.
[3] Faubion S S, Kuhle C L, Shuster L T, et al.Long-term health consequences of premature or early menopause and considerations for management[J].Climacteric, 2015, 18(4):483-491.
[4] Mitchell E S, Woods N F. Hot flush severity during the menopausal transition and early postmenopause:beyond hormones[J].Climacteric, 2015, 18(4):536-544.
[5] Chen F P, Chang C J, Chao A S, et al. Efficacy of Femarelle for the treatment of climacteric syndrome in postmenopausal women:an open label trial[J].Taiwan J Obstet Gynecol, 2016, 55(3):336-340.
[6] Greenblum C A, Rowe M A, Neff D F, et al. Midlife women:symptoms associated with menopausal transition and early postmenopause and quality of life[J].Menopause, 2013, 20(1):22-27.
[7] 谢梅青, 陈蓉, 任慕兰.中国绝经管理与绝经激素治疗指南[J].协和医学杂志, 2018, 9(6):512-525.
[8] Ahmed I S, Chamberlain C, Craven R J. S2R(Pgrmc1):the cytochrome-related sigma-2 receptor that regulates lipid and drug metabolism and hormone signaling[J].Expert Opin Drug Metab Toxicol, 2012, 8(3):361-370.
[9] Losel R M, Besong D, Peluso J J, et al.Progesterone receptor membrane component 1——many tasks for a versatile protein[J].Steroids, 2008, 73(9-10):929-934.
[10] Rohe H J, Ahmed I S, Twist K E, et al.PGRMC1(progesterone receptor membrane component 1):a targetable protein with multiple functions in steroid signaling,P450 activation and drug binding[J].Pharmacol Ther, 2009, 121(1):14-19.
[11] Kimura I, Nakayama Y, Konishi M, et al. Functions of MAPR (membrane-associated progesterone receptor) family members as hemesteroid-binding proteins[J].Curr Protein Pept Sci, 2012, 13(7):687-696.
[12] Ruan X, Zhang Y, Mueck A O, et al. Increased of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer[J].Menopause, 2017, 24(2):203-209.
[13] Zhang Y, Ruan X, Willibald M, et al.May progesterone receptor membrane component 1(PGRMC1) predict the risk of breast cancer?[J].Gynecol Endocrinol, 2016, 32(1):58-60.
[14] Mueck A O, Ruan X. Benefits and risks during HRT:main safety issue breast cancer[J].Horm Mol Biol Clin Investig, 2011, 5(2):105-116.
[15] Ruan X, Seeger H, Mueck A O. Breast cancer risk during hormone therapy:experimentalversus clinical data[J]. Minerva Endocrinol, 2012, 37(3):59-74.
[16] Yu S, Kim T, Yoo K H, et al. The T47D cell line is an ideal experimental model to elucidate the progesterone-specific effects of a luminal A subtype of breast cancer[J]. Biochem Biophys Res Commun, 2017,486(3):752-758.
[17] Peluso J J, Pappalardo A, Losel R, et al.Progesterone membrane receptor component 1 in the immature rat ovary and its role in mediating progesterone's antiapoptotic action[J].Endocrinology, 2006, 147(6):3133-3140.
[18] Peluso J J, Romak J, Liu X. Progesterone receptor membrane component-1(PGRMC1) is the mediator of progesterone's antiapoptotic action in spontaneously immortalized granulosa cells as revealed by PGRMC1 small interfering ribonucleic acid treatment and functional analysis of PGRMC1 mutations[J].Endocrinology, 2008, 149(2):534-543.
[19] Lodde V, Peluso J J. A novel role for progesterone and progesterone receptor membrane component 1 in regulating spindle microtubule stability during rat and human ovarian cell mitosis[J].Biol Reprod, 2011, 84(4):715-722.
[20] Ahmed I S, Rohe H J, Twist K E, et al.Progesterone receptor membrane component 1(Pgrmc1):a heme-1 domain protein that promotes tumorigenesis and is inhibited by a small molecule[J].J Pharmacol Exp Ther, 2010, 333(2):564-573.
[21] Zhao Y, Ruan X, Wang H, et al. The presence of a membrane-bound progesterone receptor induces growth of breast cancer with norethisterone but not with progesterone:A xenograft model[J].Maturitas, 2017, 102:26-33.
[22] Prifti S, Mall P, Strowitzki T, et al. Synthetic estrogens-mediated activation of JNK intracellular signaling molecule[J].Gynecol Endocrinol, 2001, 15(2):135-141.
[23] 刘芮菡, 孔欣,白慧丽,等.乳腺癌组织与细胞株雄激素受体生物学作用分子机制探讨[J].中华肿瘤防治杂志,2018,25(16):1163-1168.
[24] Mueck A O, Seeger H, Wallwiener D. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition[J].Climacteric, 2003, 6(3):221-227.